Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ADT and Chemotherapy in Prostate Cancer
NCT02494713Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of degarelix, pegylated liposomal doxorubicin, ketoconazole, docetaxel, estramustine in prostate cancer (PCa), sponsored by UTHealth Houston. Started Oct 2015; status: terminated.
02
Drugs
degarelixpegylated liposomal doxorubicinketoconazoledocetaxelestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02494713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494713.